Genetic engineering of attenuated malaria parasites for vaccination

Current Opinion in Biotechnology

Volumn 23, Issue 6, 2012, Pages 908-916

  Khan, Shahid M ^a   Janse, Chris J ^a   Kappe, Stefan HI ^b,c   Mikolajczak, Sebastian A ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL MODEL; BIOLOGICAL INFORMATION; CLINICAL STUDY; GENETIC MANIPULATIONS; MALARIA PARASITE; MALARIA VACCINE; PARASITE; PLASMODIUM SPOROZOITES;

DISEASES; GENETIC ENGINEERING;

VACCINES;

GENETICALLY ATTENUATED PARASITE VACCINE; LIVE VACCINE; MALARIA VACCINE; UNCLASSIFIED DRUG;

CELLULAR IMMUNITY; DEVELOPMENTAL STAGE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG POTENCY; DRUG SAFETY; GENETIC ENGINEERING; HOST PARASITE INTERACTION; HUMAN; MALARIA; MOLECULAR GENETICS; NONHUMAN; PARASITE DEVELOPMENT; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PLASMODIUM YOELII; PRIORITY JOURNAL; REVIEW; SPOROZOITE; VACCINATION; VACCINE PRODUCTION;

ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; GENETIC ENGINEERING; HUMANS; LIVER; MALARIA; MALARIA VACCINES; PLASMODIUM; SPOROZOITES; VACCINATION; VACCINES, ATTENUATED;

ANIMALIA;

EID: 84869871340     PISSN: 09581669     EISSN: 18790429     Source Type: Journal    
DOI: 10.1016/j.copbio.2012.04.003     Document Type: Review

References (65)

1. Murray C.J.L., Rosenfeld L.C., Lim S.S., Andrews K.G., Foreman K.J., Haring D., Fullman N., Naghavi M., Lozano R., Lopez A.D. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 2012, 379:413-431.
2. Greenwood B.M., Fidock D.A., Kyle D.E., Kappe S.H., Alonso P.L., Collins F.H., Duffy P.E. Malaria: progress, perils, and prospects for eradication. J Clin Invest 2008, 118:1266-1276.
3. Trape J.F., Tall A., Diagne N., Ndiath O., Ly A.B., Faye J., Dieye-Ba F., Roucher C., Bouganali C., Badiane A., et al. Malaria morbidity and pyrethroid resistance after the introduction of insecticide-treated bednets and artemisinin-based combination therapies: a longitudinal study. Lancet Infect Dis 2011, 11:925-932.
4. malERA Consultative Group on Vector Control A research agenda for malaria eradication: vector control. PLoS Med 2011, 8:e1000401.
5. malERA Consultative Group on Drugs A research agenda for malaria eradication: drugs. PLoS Med 2011, 8:e1000402.
6. malERA Consultative Group on Vaccines, Enayati A., Hemingway J. Malaria management: past, present, and future. Annu Rev Entomol 2010, 55:569-591.
7. Hill A.V. Vaccines against malaria. Philos Trans R Soc Lond B Biol Sci 2011, 366:2806-2814.
8. Greenwood B.M., Targett G.A. Malaria vaccines and the new malaria agenda. Clin Microbiol Infect 2011, 17:1600-1607.
9. malERA Consultative Group on Vaccines A research agenda for malaria eradication: vaccines. PLoS Med 2011, 8:e1000398.
10. Agnandji S.T., Lell B., Soulanoudjingar S.S., Fernandes J.F., Abossolo B.P., Conzelmann C., Methogo B.G., Doucka Y., Flamen A., Mordmüller B., et al. First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N Engl J M 2011, 365:1863-1875.
11. Gardner M.J., Hall N., Fung E., White O., Berriman M., Hyman R.W., Carlton J.M., Pain A., Nelson K.E., Bowman S., et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 2002, 419:498-511.
12. Kappe S.H., Vaughan A.M., Boddey J.A., Cowman A.F. That was then but this is now: malaria research in the time of an eradication agenda. Science 2010, 328:862-866.
13. Borrmann S., Matuschewski K. Targeting Plasmodium liver stages: better late than never. Trends Mol Med 2011, 17:527-536.
14. Hoffman S.L., Goh L.M., Luke T.C., Schneider I., Le T.P., Doolan D.L., Sacci J., de la Vega P., Dowler M., Paul C., et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 2002, 185:1155-1164.
15. Gwadz R.W., Cochrane A.H., Nussenzweig V., Nussenzweig R.S. Preliminary studies on vaccination of rhesus monkeys with irradiated sporozoites of Plasmodium knowlesi and characterization of surface antigens of these parasites. Bulletin of the World Health Organization 1979, 57(Suppl 1):165-173.
16. Nussenzweig R.S., Vanderberg J., Most H., Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 1967, 216:160-162.
17. Butler N.S., Schmidt N.W., Vaughan A.M., Aly A.S., Kappe S.H., Harty J.T. Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell Host Microbe 2011, 9:451-462.
18. Doolan D.L., Hoffman S.L. Pre-erythrocytic-stage immune effector mechanisms in Plasmodium spp. infections. Philos Trans R Soc Lond B Biol Sci 1997, 352:1361-1367.
19. Kumar K.A., Sano G., Boscardin S., Nussenzweig R.S., Nussenzweig M.C., Zavala F., Nussenzweig V. The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites. Nature 2006, 444:937-940.
20. Charoenvit Y., Mellouk S., Sedegah M., Toyoshima T., Leef M.F., De la Vega P., Beaudoin R.L., Aikawa M., Fallarme V., Hoffman S.L. Plasmodium yoelii: 17-kDa hepatic and erythrocytic stage protein is the target of an inhibitory monoclonal antibody. Exp Parasitol 1995, 80:419-429.
21. Mueller A.K., Camargo N., Kaiser K., Andorfer C., Frevert U., Matuschewski K., Kappe S.H. Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface. Proc Natl Acad Sci USA 2005, 102:3022-3027.
22. Mueller A.K., Labaied M., Kappe S.H., Matuschewski K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 2005, 433:164-167.
23. van Dijk M.R. Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells. Proc Natl Acad Sci USA 2005, 102:12194-12199.
24. Tarun A.S., Peng X., Dumpit R.F., Ogata Y., Silva-Rivera H., Camargo N., Daly T.M., Bergman L.W., Kappe S.H. A combined transcriptome and proteome survey of malaria parasite liver stages. Proc Natl Acad Sci USA 2008, 105:305-310.
25. Lasonder E., Janse C.J., van Gemert G.J., Mair G.R., Vermunt A.M., Douradinha B.G., van Noort V., Huynen M.A., Luty A.J., Kroeze H., et al. Proteomic profiling of Plasmodium sporozoite maturation identifies new proteins essential for parasite development and infectivity. PLoS Pathog 2008, 4:e1000195.
26. Kappe S.H., Gardner M.J., Brown S.M., Ross J., Matuschewski K., Ribeiro J.M., Adams J.H., Quackenbush J., Cho J., Carucci D.J., et al. Exploring the transcriptome of the malaria sporozoite stage. Proc Natl Acad Sci USA 2001, 98:9895-9900.
27. Matuschewski K., Ross J., Brown S.M., Kaiser K., Nussenzweig V., Kappe S.H. Infectivity-associated changes in the transcriptional repertoire of the malaria parasite sporozoite stage. J Biol Chem 2002, 277:41948-41953.
28. Le Roch K.G., Zhou Y., Blair P.L., Grainger M., Moch J.K., Haynes J.D., De La Vega P., Holder A.A., Batalov S., Carucci D.J., et al. Discovery of gene function by expression profiling of the malaria parasite life cycle. Science 2003, 301:1503-1508.
29. Mikolajczak S.A., Silva-Rivera H., Peng X., Tarun A.S., Camargo N., Jacobs-Lorena V., Daly T.M., Bergman L.W., de la Vega P., Williams J., et al. Distinct malaria parasite sporozoites reveal transcriptional changes that cause differential tissue infection competence in the mosquito vector and mammalian host. Mol Cell Biol 2008, 28:6196-6207.
30. Tarun A.S., Dumpit R.F., Camargo N., Labaied M., Liu P., Takagi A., Wang R., Kappe S.H. Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8+ T cells. J Infect Dis 2007, 196:608-616.
31. Overstreet M.G., Cockburn I.A., Chen Y.C., Zavala F. Protective CD8 T cells against Plasmodium liver stages: immunobiology of an 'unnatural' immune response. Immunol Rev 2008, 225:272-283.
32. Trimnell A., Takagi A., Gupta M., Richie T.L., Kappe S.H., Wang R. Genetically attenuated parasite vaccines induce contact-dependent CD8+ T cell killing of Plasmodium yoelii liver stage-infected hepatocytes. J Immunol 2009, 183:5870-5878.
33. Vaughan A.M., Wang R., Kappe S.H. Genetically engineered, attenuated whole-cell vaccine approaches for malaria. Hum Vaccin 2010, 6:107-113.
34. Luke T.C., Hoffman S.L. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J Exp Biol 2003, 206:3803-3808.
35. Annoura T., Ploemen I.H., van Schaijk B.C., Sajid M., Vos M.W., van Gemert G.J., Chevalley-Maurel S., Franke-Fayard B.M., Hermsen C.C., Gego A., et al. Assessing the adequacy of attenuation of genetically modified malaria parasite vaccine candidates. Vaccine 2012, 30:2662-2670.
36. VanBuskirk K.M., O'Neill M.T., De La Vega P., Maier A.G., Krzych U., Williams J., Dowler M.G., Sacci J.B., Kangwanrangsan N., Tsuboi T., et al. Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design. Proc Natl Acad Sci USA 2009, 106:13004-13009.
37. Annoura T., Ploemen I.H., van Schaijk B.C., Sajid M., Vos M.W., van Gemert G.J., Chevalley-Maurel S., Franke-Fayard B.M., Hermsen C.C., Gego A., et al. Assessing the adequacy of attenuation of genetically modified malaria parasite vaccine candidates. Vaccine 2012.
38. Mikolajczak S.A., Sacci J.B., De La Vega P., Camargo N., Vanbuskirk K., Krzych U., Cao J., Jacobs-Lorena M., Cowman A.F., Kappe S.H. Disruption of the Plasmodium falciparum liver stage antigen-1 locus causes a differentiation defect in late liver stage parasites. Cell Microbiol 2011.
39. van Schaijk B.C., Janse C.J., van Gemert G.J., van Dijk M.R., Gego A., Franetich J.F., van de Vegte-Bolmer M., Yalaoui S., Silvie O., Hoffman S.L., et al. Gene disruption of Plasmodium falciparum p52 results in attenuation of malaria liver stage development in cultured primary human hepatocytes. PLoS ONE 2008, 3:e3549.
40. van Schaijk B.C., Vos M.W., Janse C.J., Sauerwein R.W., Khan S.M. Removal of heterologous sequences from Plasmodium falciparum mutants using FLPe-recombinase. PLoS ONE 2010, 5:e15121.
41. O'Neill M.T., Phuong T., Healer J., Richard D., Cowman A.F. Gene deletion from Plasmodium falciparum using FLP and Cre recombinases: implications for applied site-specific recombination. Int J Parasitol 2010.
42. Sattabongkot J., Yimamnuaychoke N., Leelaudomlipi S., Rasameesoraj M., Jenwithisuk R., Coleman R.E., Udomsangpetch R., Cui L., Brewer T.G. Establishment of a human hepatocyte line that supports in vitro development of the exo-erythrocytic stages of the malaria parasites Plasmodium falciparum and P. vivax. Am J Trop Med Hyg 2006, 74:708-715.
43. Morosan S., Hez-Deroubaix S., Lunel F., Renia L., Giannini C., Van Rooijen N., Battaglia S., Blanc C., Eling W., Sauerwein R., et al. Liver-stage development of Plasmodium falciparum, in a humanized mouse model. J Infect Dis 2006, 193:996-1004.
44. Sacci J.B., Alam U., Douglas D., Lewis J., Tyrrell D.L., Azad A.F., Kneteman N.M. Plasmodium falciparum infection and exoerythrocytic development in mice with chimeric human livers. Int J Parasitol 2006, 36:353-360.
45. Azuma H., Paulk N., Ranade A., Dorrell C., Al-Dhalimy M., Ellis E., Strom S., Kay M.A., Finegold M., Grompe M. Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol 2007, 25:903-910.
46. Bissig K.D., Le T.T., Woods N.B., Verma I.M. Repopulation of adult and neonatal mice with human hepatocytes: a chimeric animal model. Proc Natl Acad Sci USA 2007, 104:20507-20511.
47. Arnold L., Tyagi R.K., Meija P., Swetman C., Gleeson J., Perignon J.L., Druilhe P. Further improvements of the P. falciparum humanized mouse model. PLoS One 2011, 6:e18045.
48. Vaughan A.M., Kappe S.H.I., Ploss A., Mikolajczak S.A. Development of humanized mouse models to study human malaria parasite infection. Future Microbiol 2012, 7.
49. Collins W.E., Sullivan J.S., Williams A., Nace D., Williams T., Galland G.G., Barnwell J.W. Aotus nancymaae as a potential model for the testing of anti-sporozoite and liver stage vaccines against Plasmodium falciparum. Am J Trop Med Hyg 2006, 74:422-424.
50. Sullivan J.S., Sullivan J.J., Williams A., Grady K.K., Bounngaseng A., Huber C.S., Nace D., Williams T., Galland G.G., Barnwell J.W., et al. Adaptation of a strain of Plasmodium falciparum from Ghana to Aotus lemurinus griseimembra. A. nancymai, and A. vociferans monkeys. Am J Trop Med Hyg 2003, 69:593-600.
51. Hoffman S.L., Billingsley P.F., James E., Richman A., Loyevsky M., Li T., Chakravarty S., Gunasekera A., Chattopadhyay R., Li M., et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin 2010, 6:97-106.
52. Epstein J.E., Tewari K., Lyke K.E., Sim B.K., Billingsley P.F., Laurens M.B., Gunasekera A., Chakravarty S., James E.R., Sedegah M., et al. Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity. Science 2011, 334:475-480.
53. Kappe S.H., Mikolajczak S.A. Immunology. Another shot at a malaria vaccine. Science 2011, 334:460-461.
54. Jobe O., Lumsden J., Mueller A.K., Williams J., Silva-Rivera H., Kappe S.H., Schwenk R.J., Matuschewski K., Krzych U. Genetically attenuated Plasmodium berghei liver stages induce sterile protracted protection that is mediated by major histocompatibility complex Class I-dependent interferon-gamma-producing CD8+ T cells. J Infect Dis 2007, 196:599-607.
55. Ishino T., Chinzei Y., Yuda M. Two proteins with 6-cys motifs are required for malarial parasites to commit to infection of the hepatocyte. Mol Microbiol 2005, 58:1264-1275.
56. van Dijk M.R., van Schaijk B.C., Khan S.M., van Dooren M.W., Ramesar J., Kaczanowski S., van Gemert G.J., Kroeze H., Stunnenberg H.G., Eling W.M., et al. Three members of the 6-cys protein family of Plasmodium play a role in gamete fertility. PLoS Pathog 2010, 6:e1000853.
57. Labaied M., Harupa A., Dumpit R.F., Coppens I., Mikolajczak S.A., Kappe S.H. Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection. Infect Immun 2007, 75:3758-3768.
58. Aly A.S., Mikolajczak S.A., Rivera H.S., Camargo N., Jacobs-Lorena V., Labaied M., Coppens I., Kappe S.H. Targeted deletion of SAP1 abolishes the expression of infectivity factors necessary for successful malaria parasite liver infection. Mol Microbiol 2008, 69:152-163.
59. Silvie O., Goetz K., Matuschewski K. A sporozoite asparagine-rich protein controls initiation of Plasmodium liver stage development. PLoS pathogens 2008, 4:e1000086.
60. Vaughan A.M., O'Neill M.T., Tarun A.S., Camargo N., Phuong T.M., Aly A.S., Cowman A.F., Kappe S.H. Type II fatty acid synthesis is essential only for malaria parasite late liver stage development. Cell Microbiol 2009, 11:506-520.
61. Yu M., Kumar T.R., Nkrumah L.J., Coppi A., Retzlaff S., Li C.D., Kelly B.J., Moura P.A., Lakshmanan V., Freundlich J.S., et al. The fatty acid biosynthesis enzyme FabI plays a key role in the development of liver-stage malarial parasites. Cell Host Microbe 2008, 4:567-578.
62. Pei Y., Tarun A.S., Vaughan A.M., Herman R.W., Soliman J.M., Erickson-Wayman A., Kappe S.H. Plasmodium pyruvate dehydrogenase activity is only essential for the parasite's progression from liver infection to blood infection. Mol Microbiol 2010, 75:957-971.
63. Ishino T., Boisson B., Orito Y., Lacroix C., Bischoff E., Loussert C., Janse C., Menard R., Yuda M., Baldacci P. LISP1 is important for the egress of Plasmodium berghei parasites from liver cells. Cellular Microbiology 2009, 11:1329-1339.
64. Haussig J.M., Matuschewski K., Kooij T.W. Inactivation of a Plasmodium apicoplast protein attenuates formation of liver merozoites. Mol Microbiol 2011, 81:1511-1525.
65. Sauerwein R.W., Roestenberg M., Moorthy V.S. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol 2011, 11:57-64.